This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Early Diagnosis and Augmentation for Alpha-1 Antitrypsin Deficiency Lung Disease: A Care Team Forum℠

Early Diagnosis and Augmentation for Alpha-1 Antitrypsin Deficiency Lung Disease: A Care Team Forum℠


Patient Case Study

Time to Complete

45 minutes


September 13, 2019


September 12, 2020
Add to Queue

Maximum Credits

0.75 AMA PRA Category 1 Credit(s)TM

Accredited Providers

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Commercial Supporter

This activity is supported by independent educational grants from CSL Behring, Grifols, and Shire, now part of Takeda.

Program Description

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that leads to an increased risk for liver and lung disease. Although more than 100,000 people in the United States have AATD, fewer than 10% of them have been diagnosed. Additionally, in those who are diagnosed, the diagnosis is delayed on average by 5.6 years. Unfortunately, the availabilty of evidence-based recommendations from the American Thoracic Society and The European Respiratory Society has done little to raise awareness about the diagnosis and management of this important condition.

This activity is designed to engage your critical thinking about patients who may have AATD and to challenge suboptimal approaches to the management of patients with AATD lung disease. You will hear unique insights from 3 clinical experts and a patient living with AATD during this dynamic presentation.

Intended Audience

Clinicians who can impact the recognition and management of patients with AATD lung disease.

Educational Objectives

After participating in this activity, you should be better able to:

  • Demonstrate improved ability to identify AATD in their patients affected by chronic obstructive pulmonary disease (COPD)
  • Identify patients at risk for AATD and implement guideline-recommended testing
  • Discuss the efficacy data and guideline recommendations for augmentation therapy use to treat AATD
  • Develop individualized treatment plans for patients with AATD using all available clinical information about the patient, including information about physiological health status

Conflict Of Interest Disclosure Policies

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Robert A. Sandhaus, MD, PhD, FCCP (Chair)
Professor of Medicine 
Director , Alpha-1 Program
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health 
Denver, CO 

Dr. Sandhaus has affiliations with Arrowhead, AstraZeneca, CSL Behring, Grifols, Inhibrx, Mereo, Takeda (Consulting Fees).

James M. Stocks, MD
Professor, Medicine
Department of Medicine
University of Texas Health Science Center at Tyler
Tyler, TX

Dr. Stocks has affiliations with CSL Behring, Grifols, Kamada (Research).

Michael A. Campos, MD, FACP
Associate Professor, Medicine 
Division of Pulmonary and Critical Care Medicine 
University of Miami School of Medicine 
Chief, Pulmonary Section 
Miami VA Medical Center 
Miami, FL 

Dr. Campos has affiliations with CSL Behring, Grifols (Consulting Fees); Grifols (Research).

Accredited Provider Disclosures

The PIM planners and managers have nothing to disclose.

Publishing Staff Disclosures

The RMEI Medical Education, LLC planners and managers have nothing to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Designation Statement

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate.

If you have any questions relating to the accreditation of this activity, please contact Postgraduate Institute for Medicine at


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue